DiaMedica Therapeutics, Inc.
(NASDAQ : DMAC)

( )
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Interested in Gold Updates?
Receive the latest updates on the gold and silver markets.
100% secure: your email is never shared, and you may opt out at any time.
...
Health Technology » Biotechnology
symbolcompany%chnglast%shortavg$volume
MRNAModerna, Inc. 4.19%220.920.0%$2054.02m
BIIBBiogen, Inc. -5.31%352.141.7%$1220.32m
NVAXNovavax, Inc. 1.23%194.6079.8%$830.44m
SNSSSunesis Pharmaceuticals, Inc. 5.73%11.770.7%$822.77m
AMGNAmgen, Inc. 0.81%240.641.3%$642.56m
BNTXBioNTech SE 0.61%230.910.0%$576.46m
VRTXVertex Pharmaceuticals, Inc. 3.00%193.151.9%$543.47m
GILDGilead Sciences, Inc. 1.59%67.711.0%$483.39m
REGNRegeneron Pharmaceuticals, Inc. 1.73%538.952.7%$392.79m
OCGNOcugen, Inc. 1.26%7.660.0%$350.34m
ILMNIllumina, Inc. 0.43%471.133.5%$348.41m
ALXNAlexion Pharmaceuticals, Inc. 0.70%181.082.0%$334.03m
TXG10X Genomics, Inc. -1.86%197.660.0%$175.39m
EXASEXACT Sciences Corp. -0.55%130.2518.1%$175.08m
BNGOBionano Genomics, Inc. -0.29%7.230.0%$155.69m

Company Profile

DiaMedica Therapeutics, Inc. operates as a clinical stage biopharmaceutical company, which engages in the development of novel recombinant proteins. It develops the DM199 product candidate, which focuses on acute ischemic stroke (AIS) and chronic kidney disease (CKD). The company was founded by Wayne Lautt on January 21, 2000 and is headquartered in Minneapolis, MN.